Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 13

Trial Status

Recruiting1
Other2

Role Distribution

Principal Investigator3
PI Rate100%

Activity Timeline

Clinical Trials (3)

NCT04594135Phase 1Unknown
Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies
T-cell Acute Lymphoblastic LeukemiaT-cell Non-Hodgkin Lymphoma
PrincipalinvestigatorStart date: 2020-12-01
NCT04162340Phase 1Unknown
CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies
Refractory T-Cell LymphomaT Cell Lymphoma in Relapse
PrincipalinvestigatorStart date: 2019-07-11
NCT04162353Phase 1Recruiting
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
Multiple Myeloma in RelapsePlasmacytoid; LymphomaRefractory Multiple Myeloma
PrincipalinvestigatorStart date: 2019-07-01

Research Network

Collaboration Network

3 collaborators·2 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Fang Liu, MD/PhD

Chengdu Military General Hospital

Moderately Similar
1 trials

Shared therapeutic areas:

Multiple Myeloma in RelapsePlasmacytoid; LymphomaRefractory Multiple Myeloma

Worked with same sponsors:

iCAR Bio Therapeutics Ltd.iCell Gene Therapeutics+1 more
Collaborated on 1 trial
Similarity Score34%

Fang Liu, MD/PhD

Chengdu Military Hospital

Related
1 trials

Shared therapeutic areas:

Refractory T-Cell LymphomaT Cell Lymphoma in Relapse

Worked with same sponsors:

iCAR Bio Therapeutics Ltd.iCell Gene Therapeutics+1 more
Collaborated on 1 trial
Similarity Score24%

Ajai Chari, MD

Icahn School of Medicine at Mount Sinai

Related
5 trials

Shared therapeutic areas:

Multiple Myeloma in RelapseRefractory Multiple Myeloma
Similarity Score9%

Steven D Reich, MD

Triphase Research and Development I Corp

Related
5 trials

Shared therapeutic areas:

Multiple Myeloma in RelapseRefractory Multiple Myeloma
Similarity Score9%

Jessica Sachs, MD

Cogent Biosciences, Inc.

Related
5 trials

Shared therapeutic areas:

Multiple Myeloma in RelapseRefractory Multiple Myeloma
Similarity Score9%

Jacalyn Rosenblatt, MD

Beth Israel Deaconess Medical Center

Related
9 trials

Shared therapeutic areas:

Refractory Multiple MyelomaMultiple Myeloma in Relapse
Similarity Score9%

Evanthia Galanis, MD

Alliance Foundation Trials, LLC.

Related
7 trials

Shared therapeutic areas:

Multiple Myeloma in RelapseRefractory Multiple Myeloma
Similarity Score9%

Leona Holmberg

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
7 trials

Shared therapeutic areas:

Refractory Multiple MyelomaT-Cell Non-Hodgkin Lymphoma
Similarity Score9%

Noelle Frey, MD

University of Pennsylvania

Related
5 trials

Shared therapeutic areas:

T-Cell Non-Hodgkin Lymphoma
Similarity Score4%

Sham Mailankody, MBBS

Memorial Sloan Kettering Cancer Center

Related
5 trials

Shared therapeutic areas:

Refractory Multiple Myeloma
Similarity Score4%

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT04594135Phase 1PrincipalInvestigator

Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies

T-cell Acute Lymphoblastic LeukemiaT-cell Non-Hodgkin Lymphoma
Unknown
NCT04162340Phase 1PrincipalInvestigator

CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies

Refractory T-Cell LymphomaT Cell Lymphoma in Relapse
Unknown
NCT04162353Phase 1PrincipalInvestigator

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

Multiple Myeloma in RelapsePlasmacytoid; LymphomaRefractory Multiple Myeloma
Recruiting

All 3 trials loaded